stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Guerbet SA

France · Euronext Paris: GBT.PA · Market cap: · P/E: · P/S:

Guerbet makes the contrast agents and injection systems that help doctors see inside the human body more clearly during medical scans.

Guerbet makes the stuff that makes medical scans actually useful. When you get an MRI or a CT scan, the machine often can't tell the difference between healthy tissue and a problem on its own — so doctors inject a contrast agent, a special liquid that lights up specific parts of the body on the image. Guerbet is one of the world's main makers of those liquids, along with the automated injection systems that deliver them safely and precisely, plus software that helps radiology departments manage their images. Its customers are hospitals and clinics, and it sells mostly through distributors and directly in major markets.

The business is older than most people guess. Guerbet started in 1926 when a French chemist, André Guerbet, developed a contrast product for X-ray imaging, and the company has stayed focused on that same basic idea for nearly a century — making the invisible visible. That focus matters, because contrast agents are a regulated, technical, trust-heavy product. You don't switch suppliers casually when the liquid is going into a patient's vein. Once a hospital standardizes on a brand and its injection protocols, it tends to stay. That stickiness, plus the need for regulatory approval in every country, makes the market hard to enter and keeps it concentrated among a handful of players, with GE HealthCare and Bayer among the biggest rivals. Guerbet is not a giant. It is a mid-sized French company with annual revenue in the high hundreds of millions of euros, and it has been investing heavily in recent years — building manufacturing capacity, developing new agents, and expanding in the United States and China. It also made a push into digital and artificial intelligence tools for radiology, betting that the future of imaging is not just the liquid but the software that surrounds it. That spending has squeezed profits at times, which is the classic mid-cap dilemma: invest for growth now and accept thinner margins, or play it safe and risk falling behind.


The honest version of the story is that Guerbet sits in a good spot with real moats — regulation, hospital habits, and technical know-how — but it is a small fish swimming near some very large ones. Its fortunes depend on continuing to win regulatory approvals, growing in the US and China, and getting paid fairly for its contrast products as health systems everywhere push to control costs. It is a quiet, specialized business that most people will never think about, until the day they lie down in a scanner and someone injects a clear liquid to help the doctor see what's wrong.

Saved answer · last researched 15 Nov 2026